Yes, you are quite right to point out the small phase 1 sample size but what Cashy said above in reply is important #: 72828706. But also, that from quite early on ithe suppression of inflammations associated with MND was noted, along with the positive results for critical biomarkers. Finally, I trust in the long medical and research experience of the trial leaders professors Mathers and Rowe. What they have said and requested is very encouraging.
Amylyx class action Relyvrio, page-42
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $93.03M | |||
| Open | High | Low | Value | Volume |
| 23.5¢ | 24.5¢ | 23.0¢ | $118.8K | 504.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 193641 | 23.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.5¢ | 34996 | 1 |
View Market Depth
| Last trade - 16.10pm 13/06/2024 (20 minute delay) ? |
|
|||||
|
Last
24.0¢ |
Change
0.000 ( 2.13 %) |
||||
| Open | High | Low | Volume | ||
| 24.0¢ | 24.0¢ | 23.5¢ | 235730 | ||
| Last updated 15.28pm 13/06/2024 ? | |||||
| PAA (ASX) Chart |